Title: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn’s Disease
Associated condition: Crohn’s disease
Status: Currently enrolling
Brief summary: This is a Phase 3, randomized, placebo-controlled study of an estimated 600 participants with moderately to severely active Crohn’s disease. Subjects in the experimental arm received subcutaneous injection of CT-P13 SC (Infliximab); those in the placebo comparator arm received a subcutaneous injection of placebo.
Primary objectives: To evaluate the efficacy and safety of the subcutaneous injection of CT-P13 (CT-P13 SC) as maintenance therapy in subjects who have moderately to severely active Crohn’s disease.
Estimated length of study: 54 weeks
For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.
